Private-Equity-Backed Medical Groups in the US · 2026 Marketing Playbook

1. Where PE money is deepest in US healthcare

Bain and Company's Global Healthcare Private Equity Report, published annually, has for the past decade tracked the same short list of US medical specialties as the deepest PE-invested segments: dermatology, ophthalmology (with cataract, retina and comprehensive-ophthal roll-ups running as separate sub-strategies), orthopedics (with strong outpatient ASC exposure), gastroenterology (with endoscopy-centre economics), plastic surgery, dental, and vision. Together those seven specialties absorb the largest share of US healthcare-services PE deal count and enterprise value year after year.

Newer categories drawing PE capital in the 2024 to 2026 window include fertility (a sector Blackstone re-entered with a large platform deal), urology (with clinician-shortage tailwinds), ENT (following the ortho and derm playbook), dermatopathology (as a lab-services adjacent bet), and behavioral health (with regulatory and reimbursement momentum). Each of these newer categories runs a smaller universe of platforms and a shorter transaction history, so a marketing partner entering the category has more room to shape the operating playbook than in a mature category like derm.

What every PE-heavy specialty shares in common: a defensible per-location EBITDA build, insurance-payer diversification (Medicare plus commercial plus self-pay in some mix), a procedure volume high enough to justify capital equipment, and a defensible referral or search-acquisition funnel. Where those four hold, the roll-up thesis works. Where any one breaks, the specialty resists roll-up (behavioral health struggled with this for years until reimbursement moved).

2. Roll-up cadence — the platform-plus-tuck-in model

The dominant PE healthcare structure is platform-plus-tuck-in. The fund identifies or seeds a "platform" acquisition — a professionally managed medical group with a real management team, clean books, working EMR, and enough scale (typically 15 to 40 locations) to absorb integration. That platform then acquires smaller "tuck-in" practices over the hold period, integrating each into the platform brand, IT stack, payer contracts and marketing programme. A well-executed platform may complete 20 to 60 tuck-ins over a five-to-seven-year hold.

The marketing implication is that the office footprint changes every quarter. A marketing plan built for 22 offices in Q1 is a plan for 34 offices by Q4 and 51 offices by year two. Every tuck-in triggers an integration workstream — brand rebrand of the acquired practice (or dual-brand transition), GBP consolidation or handover, website migration, review-portability decisions, payer-directory updates, and staff-training on the new intake stack. Marketing partners who cannot deliver integration workstreams alongside growth workstreams will fall behind the acquisition cadence and the platform's growth thesis breaks.

Two integration flavours are worth naming. Absorption keeps the platform brand and rebrands every tuck-in to it. This is common in derm and ortho platforms where a national brand carries meaningful equity. Federated keeps the acquired practice brand and layers the platform's operating support underneath, publicly invisible. This is common in plastic surgery and fertility where the local practitioner brand carries the actual patient trust. A marketing plan has to accommodate whichever flavour the platform is running, and sometimes both simultaneously across regions.

3. EBITDA-driven marketing budgets and cadence to exit

Marketing budget in a PE-backed medical group is underwritten to the fund's exit thesis. That thesis reads roughly: "over the hold period we grow same-store EBITDA at X percent, add tuck-in EBITDA at Y percent, and exit at a multiple of Z. Marketing spend contributes to same-store growth in the following ways, at the following per-location cost per new patient, with the following payback window." A marketing partner who cannot map spend into that thesis will lose the account by year three at the latest.

Cadence changes visibly across the hold. In years one and two the platform is investing to acquire volume — marketing budgets are generous, brand investments (national campaign, category-authority content) get funded, and the CMO has real budgetary authority. In years three and four the platform is tuck-in-integrating; marketing runs against per-office KPI targets, budgets stay flat, and reallocation between acquired regions becomes the dominant conversation. In years five to seven marketing budgets typically stay flat or fall in absolute terms while accountability rises — the CFO wants EBITDA multiple stability, not brand-lift narrative, and every marketing line item gets defended on contribution math.

4. Brand-central versus per-location marketing split

Every PE-backed medical group runs some flavour of the brand-central versus per-location split we described in the DSO playbook — corporate brand, national paid-media, and master creative library at the enterprise level; GBP, review response, local content, community sponsorship at the per-office level. The split is more nuanced in physician specialties than in dental because the practitioner brand often carries more patient trust than the platform brand, particularly in plastic surgery, fertility, dermatology and psychiatry.

Practical implication: the marketing partner has to design a system where the corporate brand carries reach and category authority while the practitioner brand carries trust and conversion. Well-run platforms publish practitioner-authored content (bylined, credentialed, HIPAA-clean) under the corporate brand umbrella, letting the corporate brand borrow the practitioner's credibility while the practitioner borrows the corporate brand's reach. Poorly-run platforms suppress the practitioner brand entirely and lose the conversion advantage on the specialty pages where trust matters most.

5. The MSO layer — how it changes marketing ownership

Most US PE-backed medical groups run through a Management Services Organization (MSO) structure. The MSO owns the operational infrastructure — real estate, IT, HR, billing, marketing, purchasing — and contracts with a professional corporation (PC) that is clinician-owned and provides the clinical services. This structure exists to comply with corporate-practice-of-medicine restrictions in states like California, Texas, New York and Illinois; more on that in our dedicated MSO marketing structure playbook.

Marketing sits inside the MSO in practice. Agency contracts, paid-media buying platforms, brand governance, analytics platforms, and creative production are all MSO-owned. The PC contracts with the MSO for those services. What the MSO cannot own is any clinical claim in the marketing — the claim that a specific patient outcome was achieved, the claim that a specific procedure is safe or effective, the claim that a specific clinician is the "best" at anything — because those are professional judgments that state law reserves to licensed clinicians. Practical rule: the MSO owns marketing operations; the PC owns any clinical claim on the marketing.

6. Empanelment complexity and carrier renegotiation cadence

PE-backed medical groups renegotiate payer contracts on a portfolio basis, and the leverage of size shows up in reimbursement rates. A 60-office ophthalmology platform can typically negotiate materially better in-network fee schedules than a 3-office practice would, and the platform's back-office runs credentialing and directory updates across every office and every carrier as a systemised operation rather than an ad-hoc process.

The marketing implication is that the platform's in-network directory is a live surface. When the platform renegotiates a carrier contract — adds a new carrier, drops one, changes tier — every GBP, every website page, every third-party directory listing has to reflect the new state within a defined SLA. Patients search "ophthalmologist near me who takes Aetna" and any inconsistency (office listed as in-network on the platform site but not in Aetna's own directory) will surface as a conversion loss and, at scale, a compliance risk if the marketing overstates network status. A marketing partner should build a quarterly carrier-directory audit into the retainer as a standard workstream.

7. Executive tempo — CMO, COO, CFO stakeholders

A PE-backed platform typically has three executive stakeholders for marketing. The CMO (or VP Marketing at smaller platforms) owns the brand narrative, the creative direction, the media plan, and the reporting artifact that goes to the board. The COO owns operational integration of marketing into the practice — how leads flow into the intake stack, how patient-communication follows up, how per-office marketing performance affects operational decisions. The CFO owns the budget defence, per-location contribution math, marketing ROI, and the eventual conversation with the fund LP about what marketing contributed to the exit multiple.

A marketing partner who serves only the CMO will get replaced at the first CFO-led budget review. A partner who serves only the CFO will lose the CMO's brand narrative and get out-flanked by a competitor who tells a better story. The three-stakeholder discipline: publish weekly per-location contribution reporting the COO and CFO can read, monthly brand-and-cohort analysis the CMO can present to the board, and quarterly integrated-marketing narrative that ties both together for the LP audience. Do all three or expect a shortened engagement.

8. Ichelon Consulting US\'s PE-portfolio delivery model

Ichelon Consulting US (Dallas, TX) calibrates the PE-portfolio retainer to the fund\'s hold-period stage. Early-hold platforms (years one to two) get a growth-forward retainer with brand and category-authority workstreams weighted heavily; the CMO is the primary audience. Mid-hold platforms (years three to four) get an efficiency-forward retainer with per-office KPI reporting weighted alongside the brand work; the CMO plus the COO are the primary audience. Late-hold platforms (years five plus) get a contribution-forward retainer with weekly per-location reporting, quarterly board-deck-ready summary, and a marketing-ROI defence artifact updated for every board meeting; the CFO is the primary audience.

Every retainer is HIPAA-aware by construction (vendor stack signed against BAA, patient-communication surfaces audited for TCPA, testimonial governance under OCR-safe consent), TCPA-safe on SMS and voice, and state-medical-board-aware on any clinical claim. Delivery cadence is weekly at the operating level and monthly at the board level. Book a benchmarking call from the office card below to walk through which shape fits your platform.

Frequently asked